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(57) ABSTRACT 
Microneedle devices and methods of manufacture are pro-
vided for transport of molecules or energy across or into 
biological barriers, such as skin. The device can comprise one 
or more microneedles formed of a first material and a second 
material, wherein the second material is dispersed throughout 
the first material or forms a portion of the microneedle. The 
first material preferably is a polymer. The second material can 
be pore forming agents, structural components, biosensor, or 
molecules for release, such as drug. The device also can 
comprise a substrate and a plurality of microneedles extend-
ing from the substrate, wherein the microneedles have a bev-
eled or tapered tip portion, a longitudinally extending exterior 
channel, or both. Methods of making these devices include 
providing a mold having a plurality of microdepressions 
which define the surface of a microneedle; filling the 
microdepressions with a first molding material; and molding 
the material, thereby forming microneedles. 
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MICRO NEEDLE DEVICES AND 
PRODUCTION THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
Priority is claimed to U.S. provisional application No. 
60/255,603, filed Dec. 14, 2000. 
2 
Attempts have been made to design alternative devices for 
active transfer of drugs, or analyte to be measured, through 
the skin. 
For example, U.S. Pat. No. 5,879,326 to Godshall et al. and 
PCT WO 96/37256 by Silicon Microdevices, Inc. disclose a 
transdermal drug delivery apparatus that includes a cutter 
portion having a plurality of microprotrusions, which have 
straight sidewalls, extending from a substrate that is in com-
munication with a drug reservoir. In operation, the micropro-
BACKGROUND OF THE INVENTION 
This invention is generally in the field of devices for the 
controlled transport of molecules across tissue barriers, such 
as for drug delivery or sampling of biological fluids. 
10 trusions penetrate the skin until limited by a stop region of the 
substrate and then are moved parallel to the skin to create 
incisions. Channels in the substrate adjacent to the micropro-
trusions allow drug from the reservoir to flow to the skin near 
the area disrupted by the microprotrusions. 
U.S. Pat. No. 5,250,023 to Lee et aL. discloses a transder-
mal drug delivery device, which includes a plurality of 
needles having a diameter in the range of 50 to 400 µm. The 
needles are supported in a water-swellable polymer substrate 
through which a drug solution permeates to contact the sur-
Numerous drugs and therapeutic agents have been <level- 15 
oped in the battle against disease and illness. A frequent 
limitation to the effective and efficient use of these drugs, 
however, is their delivery, that is, how to transport the drugs 
across biological barriers in the body (e.g., the skin, the oral 
mucosa, the blood-brain barrier), which normally do not 
transport drugs at rates that are therapeutically useful or opti-
mal. 
20 face of the skin. An electric current is applied to the device to 
open the pathways created by the needles, following their 
withdrawal from the skin upon swelling of the polymer sub-
strate. Drugs are commonly administered orally as pills or cap-
sules. Many drugs, however, cannot be effectively delivered 
in this manner, due to degradation in the gastrointestinal tract 25 
and/or elimination by the liver. Moreover, some drugs cannot 
effectively diffuse across the intestinal mucosa. Patient com-
pliance may also be a problem, for example, in therapies 
requiring that pills be taken at particular intervals over a 
prolonged time. 30 
PCT WO 93/177 54 by Gross et al. discloses another trans-
dermal drug delivery device that includes a housing having a 
liquid drug reservoir and a plurality of tubular elements for 
transporting liquid drug into the skin. The tubular elements 
may be in the form of hollow needles having inner diameters 
ofless than 1 mm and an outer diameter of 1.0 mm. 
While each of these devices has potential use, there 
remains a need for better drug delivery devices, which make 
smaller punctures or incisions, deliver drug with greater effi-
ciency (greater drug delivery per quantity applied) and less 
variability of drug administration, and/or are easier to use. In 
view of these needs, microneedle devices have been devel-
oped, which are described in U.S. Ser. Nos. 09/095,221, filed 
Jun. 10, 1998, and 09/316,229, filed May 21, 1999, both by 
Prausnitz et al., and PCT WO 99/64580 and PCT WO 
00/74763, which are hereby incorporated by reference. It 
Another common technique for delivering drugs across a 
biological barrier is the use of a conventional needle, such as 
those used with standard syringes or catheters, to transport 
drugs across (through) the skin. While effective for this pur-
pose, needles generally cause pain, local damage to the skin at 35 
the site of insertion, bleeding, which increases the risk of 
disease transmission, and a wound sufficiently large to be a 
site of infection. Needle techniques also generally require 
administration by one trained in its use, and are undesirable 
for long-term, controlled continuous drug delivery. 40 would be advantageous, however, to provide additional meth-
ods of manufacturing devices having microneedles, particu-
larly using materials and processes that are cost-effective and 
expand the range of useful properties and functions of the 
microneedles. It would also be useful to have biocompatible 
Similarly, current methods of withdrawal or sampling 
bodily fluids, such as for diagnostic purposes, using a con-
ventional needle are invasive and suffer from the same disad-
vantages. For example, needles or lancets are not preferred 
for frequent routine use, such as sampling of a diabetic's 
blood glucose or delivery of insulin, due to the vascular 
damage caused by repeated punctures. No alternative meth-
odologies are currently in use. Proposed alternatives to the 
needle require the use of lasers or heat to create a hole in the 
skin, which is inconvenient, expensive, or undesirable for 
repeated use. 
45 and biodegradable microneedles and increased ease of manu-
facture. 
It is therefore an object of the present invention to provide 
an expanded selection of methods and materials for making 
and using microneedle devices for relatively painless, con-
50 trolled and safe delivery or withdrawal of molecules across 
biological barriers such as skin. 
It is a further object of the present invention to provide 
microneedle devices which can be produced inexpensively. 
It is another object of the present invention to provide 
55 techniques for producing complex microneedle structures, 
yielding a variety of useful properties and functions of the 
microneedles. 
An alternative delivery technique is the transdermal patch, 
which usually relies on diffusion of the drug across the skin. 
However, this method is not useful for many drugs, due to the 
poor permeability (i.e. effective barrier properties) of the 
skin. The rate of diffusion depends in part on the size and 
hydrophilicity of the drug molecules and the concentration 
gradient across the stratum corneum. Few drugs have the 
necessary physiochemical properties to be effectively deliv-
ered through the skin by passive diffusion. Iontophoresis, 60 
electroporation, ultrasound, and heat (so-called active sys-
tems) have been used in an attempt to improve the rate of 
delivery. While providing varying degrees of enhancement, 
these techniques are not suitable for all types of drugs, failing 
to provide the desired level of delivery. In some cases, they are 65 
also painful and inconvenient or impractical for continuous 
controlled drug delivery over a period of hours or days. 
SUMMARY OF THE INVENTION 
Microneedle devices for transport of molecules, including 
drugs and biological molecules, across biological barriers, 
such as tissue or cell membranes, are provided, along with 
methods for their manufacture and use. In one embodiment, 
the device comprises one or more microneedles formed of a 
first material and a second material, wherein the second mate-
rial is dispersed throughout the first material or forms a por-
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tion of the microneedle. The second material can be pore 
forming agents, structural components, biosensors, or mol-
ecules for release, such as drug (e.g., a vaccine). In another 
embodiment, the device comprises a substrate and a plurality 
of microneedles extending from the substrate, wherein the 
microneedles have a beveled or tapered tip portion, a longi-
tudinally extending exterior channel, or both. 
In a preferred embodiment, the microneedles are formed of 
4 
In variations of this method, step (ii) can further comprise 
(a) applying a sacrificial polymer layer to the substrate to the 
height of the formed microneedles; (b) patterning a metal 
layer onto the surface of the sacrificial polymer layer of 
polymeric material to form a patterned etch mask; and ( c) 
using reactive ion etching to shape the tip portion of the 
microneedles. The patterned etch mask can be placed asym-
metrically over the microneedles, effective to form micron-
eedles having a beveled tip, or placed symmetrically over the a biocompatible and biodegradable polymer, such as polylac-
tide, polyglycolide, and copolymers and blends thereof. The 
microneedles also can include, or be formed of, drug and/or 
additives or excipients. The polymer microneedles also can 
10 microneedles, effective to form microneedles having a sym-
metrical tapered tip. 
be fabricated to provide a microneedle having a defined 
porosity or having particles of reinforcing material distrib- 15 
uted within the microneedle. 
Methods for manufacturing these microneedle devices 
include micromolding, microfabrication, microshaping, and 
combinations thereof. In a preferred method, the steps 
include providing a mold having a plurality of microdepres- 20 
sions which define the surface of a microneedle; filling the 
microdepressions with a molding material; and molding the 
material, thereby forming microneedles. The molding meth-
ods are useful for forming microneedles from polymer, met-
als, and other materials. The methods enable the formation of 25 
microneedles having composite or layered structures which 
provide a control over the time and rate of release of drug or 
other agent and/or affect the mechanical properties of the 
microneedles. Porous microneedles can be formed by dis-
persing a leachable or volatilizable pore-forming agent in the 30 
microneedle material prior to forming the microneedles and 
then leaching or volatilizing the pore-forming agent from the 
microneedles. 
In one embodiment, micromolds are filled with liquid 
monomer or a solution of monomer, the monomer is poly- 35 
merized, and the polymer is directly or indirectly converted to 
a solid form in the shape of the microneedles. Alternatively, 
the micromold is filled with polymer powder, heated to melt 
the polymer, and then cooled to solidify the polymer in the 
shape of the microneedles. In another variation, the solid 40 
polymer can be exposed to carbon dioxide in amounts and 
under conditions effective to swell the polymer particles to 
form them together. The polymer powder also can be molded 
by compression molding. In a preferred embodiment, poly-
mer melting is conducted under reduced pressure (e.g., 45 
vacuum conditions) in order to pull the polymer into the mold 
and displace any trapped gases, thereby minimizing or elimi-
nating the formation of void defects in the microneedles. This 
approach overcomes the surface tension/wetting problems 
which can occur in large scale molding operations. 50 
In another embodiment, the method comprises (i) forming 
one or more layers of a monomer or polymer material on a 
substrate; and (ii) selectively removing portions of the mono-
mer or polymer material to form microneedles on the sub-
strate. The monomer or polymer material on the substrate can 55 
comprise a first layer of a first material and a second layer of 
a second material, and can be crosslinkable. In the latter case, 
step (ii) can comprise using an optical mask to crosslink 
selected portions of the crosslinkable material; and then 
developing the uncrosslinked portions of the crosslinkable 60 
material, wherein the remaining crosslinked material forms 
the microneedles extending from the substrate. The optical 
mask can comprise a filled circle having one or more notches 
therein, effective to form a microneedle having a longitudi-
nally extending exterior charmel. The optical etch mask also 65 
can comprise a donut shape, effective to form a hollow 
microneedle or microneedle having a closed bore. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. la-g illustrate a process of fabricating polymer 
microneedles, shown in cross-section, using a silicone mold. 
FIGS. 2a-g illustrate a process of fabricating polymer 
microneedles, shown in cross-section, using reactive ion 
etching. 
FIG. 3 is a cross-sectional view of one embodiment of a 
device having microneedles formed of multiple layers of 
different polymeric materials. 
FIG. 4 is a micrograph of an interim structure in the fabri-
cation process illustrated in FIG. llc. 
FIG. 5 is a side elevational view of a schematic of an 
embodiment of the microneedle device inserted into unde-
formed skin. 
FIGS. 6a-g illustrate a process of fabricating hollow poly-
meric microneedles, shown in cross-section, using a combi-
nation of photo lithography and micromolding. 
FIGS. 7a-k illustrate a process of fabricating solid poly-
meric microneedles having a tapered tip, shown in cross-
section, using a combination of photo lithography and micro-
molding. 
FIGS. Sa-i illustrate a process of fabricating solid poly-
meric microneedles having a beveled tip, shown in cross-
section, using a combination of photo lithography and micro-
molding. 
FIG. 9 is a micrograph of solid polymeric microneedles 
having a longitudinal channel. 
FIGS. lOa-b are micrographs of a solid polymeric micron-
eedles having a beveled tip portion. 
FIGS. lla-g illustrate a process of fabricating solid poly-
meric microneedles having an obelisk shape, shown in cross-
section, using a combination of photo lithography and micro-
molding. 
FIG. 12 is a micrograph of an array of solid polymeric 
microneedles having an obelisk shape. 
DETAILED DESCRIPTION OF THE INVENTION 
1. Biological Barriers 
The devices disclosed herein are useful in transport of 
material into or across biological barriers including the skin 
(or parts thereof); the blood-brain barrier; mucosa! tissue 
(e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, 
respiratory); blood vessels; lymphatic vessels; or cell mem-
branes (e.g., for the introduction of material into the interior 
of a cell or cells). The biological barriers can be in humans or 
other types of animals, as well as in plants, insects, or other 
organisms, including bacteria, yeast, fungi, and embryos. The 
microneedle devices can be applied to tissue internally with 
the aid of a catheter or laparoscope. For certain applications, 
such as for drug delivery to an internal tissue, the devices can 
be surgically implanted. 
In a preferred embodiment, the microneedle device dis-
closed herein is applied to skin. The stratum corneum is the 
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outer layer, generally between 10 and 50 cells, or between 10 
and 20 µm thick. Unlike other tissue in the body, the stratum 
corneum contains "cells" (called keratinocytes) filled with 
bundles of cross-linked keratin and keratohyalin surrounded 
by an extracellular matrix of lipids. It is this structure that is 
believed to give skin its barrier properties, which prevents 
therapeutic transdermal administration of many drugs. Below 
the stratum corneum is the viable epidermis, which is 
between 50 and 100 µm thick. The viable epidermis contains 
no blood vessels, and it exchanges metabolites by diffusion to 
and from the dermis. Beneath the viable epidermis is the 
dermis, which is between 1 and 3 mm thick and contains 
blood vessels, lymphatics, and nerves. 
As used herein, references to using the microneedle 
devices on "skin" also include using the microneedle devices 
with other biological barriers unless expressly limited to only 
skin. 
2. The Microneedle Device 
The microneedle devices disclosed herein include a sub-
6 
degradable hydrogels also be useful as a matrix material. 
Representative non-biodegradable polymers include poly-
acrylates, polymers of ethylene-vinyl acetates and other acyl 
substituted cellulose acetates, non-degradable polyurethanes, 
polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vi-
nyl imidazole ), chlorosulphonate polyolefins, polyethylene 
oxide, blends and copolymers thereof. 
In one embodiment, the microneedle includes or is formed 
of drug. For example, drug particles can be dispersed in a 
10 polymer liquid or polymer solution which is then micro-
molded. In another example, the drug molecules are encap-
sulated or linked with the material forming the microneedle 
structure, for example, a biodegradable polymer. In one spe-
cific embodiment of this example, the drug is a vaccine and 
15 the matrix material (forming the needle structure) degrades 
into adjuvants useful for the vaccine. In yet another example, 
the microneedle is composed of a drug material. Other addi-
tives or excipient materials can be included in the micron-
eedle structure and are described below. 
In a preferred embodiment, the microneedle is formed 
from two or more materials. The two (or more) materials can 
be combined heterogeneously or as a homogeneous mixture. 
For example, the materials can be different metals, different 
polymers, or combinations of metals and polymers. For 
strate; one or more microneedles; and, optionally, a reservoir 20 
for delivery of drugs or collection of analyte. The devices also 
can include one or more pumps (or other mechanisms for 
inducing flow through needle bores, channels or pores), sen-
sors, and/or microprocessors to control the interaction of the 
foregoing. 25 example, in the heterogeneous embodiments, the materials 
can be built up in layers, such that the composition varies 
along the shaft of the microneedle, or the microneedle can 
have a core of a first material with a coating of a second 
material formed onto the core. Additional layers of the first or 
a. Substrate 
The substrate of the device can be constructed from a 
variety of materials, including metals, ceramics, semiconduc-
tors, organics, polymers, and composites. Polymers, copoly-
mers, blends, and composites of polymers with other materi-
als are preferred. The substrate includes the base to which the 
microneedles are attached or integrally formed. One or more 
reservoirs may also be attached to, or formed in, the substrate. 
30 other materials could also be included onto the second mate-
rial. In another variation, the second material is filled into 
voids or pores within a matrix of the first material. 
Structure 
In one embodiment of the device, the substrate is formed 
from a thin, rigid material that is sufficiently stiff to force the 35 
microneedles through the biological barrier in such areas 
where the barrier resists deformation by the microneedles. In 
another embodiment of the device, the substrate is formed 
from flexible materials to allow the device to fit the contours 
Generally, the microneedles should have the mechanical 
strength to remain intact for delivery of drugs or for serving as 
a conduit for the collection of biological fluid, while being 
inserted into the skin, while remaining in place for seconds up 
to a number of days, and while being removed. In embodi-
ments where the microneedles are formed of biodegradable 
of the biological barrier, and to adapt to barrier deformations 
that may occur when the microneedle device is applied. A 
flexible device may facilitate more consistent penetration 
during use, since penetration can be limited by deviations in 
the attachment surface. For example, the surface of human 
skin is not flat due to dermatoglyphics, i.e. tiny wrinkles, and 
hair, and is highly deformable. The flexible substrate can be 
deformed mechanically (for example, using an actuator or 
simply by fluid pressure) in order to pierce the biological 
barrier. 
b. Microneedle 
The microneedles can be oriented perpendicular or at an 
angle to the substrate. Preferably, the microneedles are ori-
ented perpendicular to the substrate so that a larger density of 
microneedles per unit area of substrate is provided. An array 
of microneedles can include a mixture of microneedle orien-
tations, heights, or other parameters. 
Materials of Construction 
The microneedles of the device can be constructed from a 
variety of materials, including metals, ceramics, semiconduc-
tor materials, and composites, but preferably are formed of a 
polymer, particularly a biocompatible polymer. The polymer 
can be biodegradable or non-biodegradable. Examples of 
suitable biocompatible, biodegradable polymers include poly 
(lactide )s, poly(glycolide )s, poly(lactide-co-glycolide )s, 
polyanhydrides, polyorthoesters, polyetheresters, polycapro-
lactones, polyesteramides, poly(butyric acid), poly(valeric 
acid), polyurethanes and copolymers and blends thereof. Bio-
40 polymers and/or drugs, however, the microneedles or tips 
thereof can be intentionally broken off, for example in the 
skin, and will biodegrade and release drug. Biodegradable 
hollow or porous microneedles that provide a conduit func-
tion should remain intact long enough to deliver or withdraw 
45 the desired quantity of molecules. Biodegradable micron-
eedles can provide an increased level of safety compared to 
nonbiodegradable ones, such that they are essentially harm-
less even ifinadvertently broken off into the skin. This applies 
whether the microneedles contain molecules for delivery or 
50 serve merely a conduit function. 
The microneedles can be formed of a nonporous or porous 
solid (with or without a sealed coating or exterior portion), 
and can be hollow. As used herein, the term "porous" means 
having pores or voids throughout at least a portion of the 
55 microneedle structure, sufficiently large and sufficiently 
interconnected to permit passage of fluid and/or solid mate-
rials into or through the microneedle. As used herein, the term 
"hollow" means having one or more bores or channels 
through the interior and along a substantial portion of the 
60 length of the microneedle structure, having a diameter suffi-
ciently large to permit passage of fluid and/or solid materials 
through the microneedle. The bores are preferably annular, 
and may extend throughout all or a portion of the needle in the 
direction of the tip to the base, extending parallel to the 
65 direction of the needle or branching or exiting at a side of the 
needle, as appropriate. A solid or porous microneedle can be 
hollow. One of skill in the art can select the appropriate 
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porosity and/or bore features required for specific applica-
tions. For example, one can adjust the pore size or bore 
diameter to permit passage of the particular material to be 
transported through the microneedle device. The inner sur-
face of the bore ofhollow microneedles can be made rough to 
enhance cell membrane disruption for those applications in 
which cell disruption is useful. 
In a preferred embodiment, the exterior surface of the 
microneedle shaft includes one or more channels (i.e. a notch 
or groove) extending longitudinally along the shaft. The 10 
channel can serve as a conduit, for drug delivery or fluid 
withdrawal, following insertion of the microneedle into a 
biological barrier. Alternatively, the channel can be filled with 
a matrix material containing a drug or with a biosensor. The 
drug would then be released at a controlled rate following 15 
microneedle insertion, by diffusion of the drug from the 
matrix, degradation of the matrix material, or a combination 
thereof. 
8 
portion having a square cross-section, such that the micron-
eedle is in the shape of an obelisk. Of course, the tip and/or 
shaft can be rounded, or have another shape, as well. The tip 
portion preferably has a height that is less than 50% of the 
height of the height of the microneedle. The beveled or obe-
lisk structures advantageously provides better mechanical 
properties than fully tapered microneedles. 
Dimensions 
The microneedles preferably have a width or cross-sec-
tional dimension between about 1 µm and 500 µm, more 
preferably between 10 µm and 100 µm. For hollow micron-
eedles, the outer diameter or width is typically between about 
10 µm and about 100 µm, and the inner diameter is typically 
between about 3 µm and about 80 µm. 
The length of the microneedle can be selected for the 
particular application, and typically would account for both 
an inserted and uninserted portion. Shorter microneedles 
would be useful for example for penetrating individual cells 
or penetrating just into the stratum corneum. In contrast, the In another embodiment, the microneedle includes a closed 
bore. By closed bore is meant that the microneedle includes 20 longer needles might be useful for example for penetrating 
into the dermis. The methods described herein enable one to an opening at the needle tip which extends into the shaft of the 
microneedle and terminates at or nearthe base of the micron-
eedle. This closed bore can be loaded with a drug or a matrix 
material that includes drug, such that the drug can be released 
from the bore opening following microneedle insertion. The 25 
drug would then be released at a controlled rate by diffusion 
of the drug from the matrix, degradation of the matrix mate-
rial, or a combination thereof. The closed bore alternatively 
could include a biosensor or be used in sensing or fluid with-
drawal. 
Alternatively, the bore could be closed at the tip, so that 
bore is exposed (opened) only upon intentionally breaking off 
the microneedles following insertion. This might be useful 
for delivery of the molecules inside the bore to skin surface. 
30 
make a particular size needed for a particular application. 
In some embodiments, the microneedles have length of at 
least about 30 microns (e.g., at least about 50 microns, at least 
about 100 microns, at least about 250 microns). In certain 
embodiments, the microneedles have a length of at most 
about 1000 microns (e.g., at most about 900 microns, at most 
about 800 microns, at most about 700 microns, at most about 
600 microns, at most about 500 microns. 
In other embodiments, the microneedles have length of at 
least about 500 microns (e.g., at least about 600 microns, at 
least about 700 microns, at least about 800 microns, at least 
about 900 microns). In certain embodiments, the micron-
eedles have a length of at most about 1500 microns (e.g., at 
In the channel and closed bore embodiments, the drug 
matrix material (in the bore or channel) preferably can be 
selected without considering its mechanical strength proper-
ties, as the remainder of the microneedle structure can pro-
vide the mechanical strength needed to penetrate the biologi-
cal barrier. In addition, in the channel and closed bore 
embodiments, the rate of drug delivery can be controlled by 
selecting different size bores or channels and/or different 
matrix materials. 
35 most about 1400 microns, at most about 1300 microns, at 
most about 1200 microns, at most about 1000 microns). 
Exemplary ranges for microneedle lengths include, from 
about 800 microns to about 1100 microns (e.g., from about 
900 microns to about 1000 microns, from about 930 microns 
40 to about 970 microns, about 950 microns). 
In another embodiment, polymer microneedles are rein-
forced with metal to provide additional structural strength. 45 
This could be achieved by fabricating a metal core with a 
polymer coating around it. This could also be achieved with a 
lattice of metal within a polymer needle. In this way, the 
polymer material can be selected based on drug delivery, 
biocompatibility and other considerations, while the metal is 50 
selected based on mechanical considerations. 
The microneedles can have straight or tapered shafts. In 
one embodiment, the diameter of the microneedle is greatest 
at the base end of the microneedle and tapers to a point at the 
end distal the base. The microneedle can also be fabricated to 55 
have a shaft that includes both a straight (untapered) portion 
and a tapered portion. The microneedles can be formed with 
shafts that have a circular cross-section in the perpendicular, 
or the cross-section can be non-circular. For example, the 
cross-section of the microneedle can be polygonal (e.g. star- 60 
shaped, square, triangular), oblong, or another shape. 
The tip portion of the microneedles can have a variety of 
configurations. The tips can be symmetrical or asymmetrical 
about the longitudinal axis of the microneedle shaft. In a 
preferred embodiment, the tips are beveled. In another 65 
embodiment, the tip portion is tapered. In one embodiment, 
the tapered tip portion is in the shape of a pyramid on a shaft 
The microneedles preferably are fabricated to have an 
aspect ratio 1: 10 and 1: 100, more preferably between about 
1 :2 and 1 :20, and more preferably between about 1 :3 and 
1:10. 
An array of microneedles can include a mixture of micron-
eedles having, for example, various lengths, outer diameters, 
inner diameters, cross-sectional shapes, and spacing between 
the microneedles. 
c. Reservoir 
The microneedle device may include a reservoir in com-
munication with the microneedles. The reservoir can be 
attached to the substrate by any suitable means. In a preferred 
embodiment, the reservoir is attached to the back of the sub-
strate (opposite the microneedles) around the periphery, 
using an adhesive agent (e.g., glue). A gasket may also be 
used to facilitate formation of a fluid-tight seal. 
In a preferred embodiment, the reservoir contains drug for 
delivery through the microneedles. The reservoir may be a 
hollow vessel, a porous matrix, or a solid form including drug 
which is transported therefrom. The reservoir can be formed 
from a variety of materials that are compatible with the drug 
or biological fluid contained therein. Preferred materials 
include natural and synthetic polymers, metals, ceramics, 
semiconductors, organics, and composites. In one embodi-
ment, the reservoir is a standard syringe. 
The microneedle device can include one or a plurality of 
chambers for storing materials to be delivered. In the embodi-
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ment having multiple chambers, each can be in fluid connec-
tion with all or a portion of the microneedles of the device 
array. In one embodiment, at least two chambers are used to 
separately contain drug (e.g., a lyophilized drug, such as a 
vaccine) and an administration vehicle (e.g., saline) in order 
10 
forces, such as electroosmosis or electrophoresis, or convec-
tion. For example, in electroosmosis, electrodes are posi-
tioned on the biological barrier surface, one or more micron-
eedles, and/or the substrate adjacent the needles, to create a 
convective flow which carries oppositely charged ionic spe-
cies and/or neutral molecules toward or into the biological 
barrier. In a preferred embodiment, the microneedle device is 
used in combination with another mechanism that enhances 
the permeability of the biological barrier, for example by 
to prevent or minimize degradation during storage. Immedi-
ately before use, the contents of the chambers are mixed. 
Mixing can be triggered by any means, including, for 
example, mechanical disruption (i.e. puncturing or breaking), 
changing the porosity, or electrochemical degradation of the 
walls or membranes separating the chambers. In another 
embodiment, a single device is used to deliver different drugs, 
which are stored separately in different chambers. In this 
embodiment, the rate of delivery of each drug can be inde-
pendently controlled. 
10 increasing cell uptake or membrane disruption, using electric 
fields, ultrasound, chemical enhancers, vacuum viruses, pH, 
heat and/or light. 
Passage of the microneedles, or drug to be transported via 
the microneedles, can be manipulated by shaping the micron-
15 eedle surface, or by selection of the material forming the 
microneedle surface (which could be a coating rather than the 
microneedleperse). For example, one or more grooves on the 
outside surface of the microneedles can be used to direct the 
In a preferred embodiment, the reservoir should be in direct 
contact with the microneedles and have holes through which 
drug could exit the reservoir and flow into the interior of 
hollow or porous microneedles. In another embodiment, the 
reservoir has holes which permit the drug to transport out of 20 
the reservoir and onto the skin surface. From there, drug is 
transported into the skin, either through hollow or porous 
microneedles, along the sides of microneedles, or through 
pathways created by microneedles in the skin. 
passage of drug, particularly in a liquid state. Alternatively, 
the physical surface properties of the microneedle can be 
manipulated to either promote or inhibit transport of material 
along the microneedle surface, such as by controlling hydro-
philicity or hydrophobicity. 
The flow of molecules can be regulated using a wide range 
d. Transport Control Components 25 of valves or gates. These valves can be the type that are 
selectively and repeatedly opened and closed, or they can be 
single-use types. For example, in a disposable, single-use 
drug delivery device, a fracturable barrier or one-way gate 
The microneedle device also must be capable of transport-
ing material across the barrier at a useful rate. For example, 
the microneedle device must be capable of delivering drug 
across the skin at a rate sufficient to be therapeutically useful. 
The device may include a housing with microelectronics and 30 
other micromachined structures to control the rate of delivery 
either according to a preprogrammed schedule or through 
active interface with the patient, a healthcare professional, or 
may be installed in the device between the reservoir and the 
opening of the microneedles. When ready to use, the barrier 
can be broken or gate opened to permit flow through the 
microneedles. Other valves or gates used in the microneedle 
devices can be activated thermally, electrochemically, 
mechanically, or magnetically to selectively initiate, modu-
late, or stop the flow of molecules through the needles. In a 
preferred embodiment, flow is controlled by using a rate-
limiting membrane as a "valve." 
The microneedle devices can further include a flowmeter 
a biosensor. The rate can be controlled by manipulating a 
variety of factors, including the characteristics of the drug 35 
formulation to be delivered (e.g., its viscosity, electric charge, 
and chemical composition); the dimensions of each micron-
eedle (e.g., its outer diameter and the area of porous or hollow 
openings); the number of microneedles in the device; the 
application of a driving force (e.g., a concentration gradient, 
or other means to monitor flow through the microneedles and 
40 to coordinate use of the pumps and valves. 
a voltage gradient, a pressure gradient); and the use of a valve. 
Alternatively, the rate of delivery can be controlled by select-
ing the rate of biodegradation or dissolution of the micron-
eedles formed of drug or formed of a biodegradable matrix 
having drug dispersed within the matrix, for example by 45 
selection of the appropriate polymeric matrix material. 
e. Sensors 
Useful sensors may include sensors of pressure, tempera-
ture, chemicals, and/or electro-magnetic fields. Biosensors 
can be located on the microneedle exterior surface (e.g., in a 
channel), inside a microneedle (inside a bore or pores), or 
inside a device in communication with the body tissue via the 
microneedle (solid, hollow, or porous). These microneedle 
biosensors can include four classes of principal transducers: 
potentiometric, amperometric, optical, and physiochemical. 
An amperometric sensor monitors currents generated when 
electrons are exchanged between a biological system and an 
electrode. Blood glucose sensors frequently are of this type. 
The microneedle may function as a conduit for fluids, 
solutes, electric charge, light, or other materials. In one 
The rate also can be controlled by interposing between the 
drug in the reservoir and the opening( s) at the base end of the 
microneedle polymeric or other materials selected for their 
diffusion characteristics. For example, the material composi- 50 
tion and layer thickness can be manipulated using methods 
known in the art to vary the rate of diffusion of the drug of 
interest through the material, thereby controlling the rate at 
which the drug flows from the reservoir through the micron-
eedle and into the tissue. 55 embodiment, hollow microneedles (or those having a bore or 
channel) can be filled with a substance, such as a gel, that has 
a sensing functionality associated with it. In an application for 
sensing based on binding to a substrate or reaction mediated 
by an enzyme, the substrate or enzyme can be immobilized in 
Transportation of molecules through the microneedles can 
be controlled or monitored using, for example, various com-
binations of valves, pumps, sensors, actuators, and micropro-
cessors. These components can be produced using standard 
manufacturing or micro fabrication techniques. Actuators that 
may be useful with the microneedle devices disclosed herein 
include micropumps, microvalves, and positioners. In one 
embodiment, a microprocessor is programmed to control a 
pump or valve, thereby controlling the rate of delivery. 
Flow of molecules through the microneedles can occur 
based on diffusion, capillary action, or can be induced using 
conventional mechanical pumps or nonmechanical driving 
60 the needle interior, which would be especially useful in a 
porous needle to create an integral needle/sensor. 
Wave guides (e.g., PMMA) can be incorporated into the 
microneedle device to direct light to a specific location, or for 
detection, for example, using means such as a pH dye for 
65 color evaluation. Similarly, heat, electricity, light or other 
energy forms may be precisely transmitted to directly stimu-
late, damage, or heal a specific tissue or intermediary (e.g., 
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tattoo removal for dark skinned persons), or diagnostic pur-
poses, such as measurement of blood glucose based on IR 
spectra or by chromatographic means, measuring a color 
change in the presence of immobilized glucose oxidase in 
combination with an appropriate substrate. 
f. Attachment Features 
12 
probably be stored in the refrigerator to prevent a premature 
phase change. These voids could be useful as transport path-
ways (porous/hollow needle) or plugs removed to initiate 
drug release. The hydrates could also be structurally reinforc-
ing agents which disappear after insertion into the body, thus 
preventing re-use. 
The second function is one where the additive is left in the 
microneedle and removed after insertion. For example, the 
additive can be a salt that is dissolved away upon contact with 
water in the biological barrier. The removal of the additive can 
initiate release of drug that is stored within the microneedles 
or in a reservoir in communication with the microneedles. 
The release kinetics can be controlled, for example, by selec-
tion of the rate of dissolution and/or degradation of the addi-
A collar or flange also can be provided with the device, for 
example, around the periphery of the substrate or the base. It 
preferably is attached to the device, but alternatively can be 
formed as an integral part of the substrate, for example by 10 
forming microneedles only near the center of an "oversized" 
substrate. The collar can also emanate from other parts of the 
device. The collar can provide an interface to attach the 
microneedle array to the rest of the device, and can facilitate 
handling of the smaller devices. 
In a preferred embodiment, the microneedle device 
includes an adhesive to temporarily secure the device to the 
surface of the biological barrier. The adhesive can be essen-
tially anywhere on the device to facilitate contact with the 
biological barrier. For example, the adhesive can be on the 20 
surface of the collar (same side as microneedles), on the 
surface of the substrate between the microneedles (near the 
base of the microneedles), or a combination thereof. 
15 tive and/or polymer. For example, the bulk of the microneedle 
can be a slowly- or non-degradable polymer having dispersed 
therein rapidly-degradable polymer particles. The additive 
may function to enhance the structural strength of the micron-
In one embodiment, the microneedle device is incorpo-
rated into an arm (e.g., wrist) band. The armband can be 25 
conveniently worn by a patient for drug delivery, sampling of 
biological fluids, or both over a prolonged period, such as 
several hours. 
eedles, but only for a single insertion (e.g. to enhance safety 
by rendering the microneedles unsuitable for reuse/misuse). 
Then, following insertion, the additive dissolves away to ren-
der the microneedles too weak to penetrate the biological 
barrier without structural failure. The additive for this func-
tion should be soluble or degradable upon contact with the 
biological fluids present in the biological barrier to be pen-
etrated. The additive is selected, for example, based on the pH 
and temperature of these aqueous fluids. 
In the third function, the additive remains, typically to 
serve a structural function (i.e. to lend mechanical strength or g. Additives/Excipient Materials Used in Forming the 
Microneedles 
The microneedles can include an additive which (1) is 
removed before insertion of the microneedles into the bio-
logical barrier; (2) is removed while the microneedles are 
inserted in the biological barrier; or (3) remains in the micron-
eedle. 
30 rigidity to the microneedles). For example, a dispersion of 
rigid salt particles in PLGA can enhance the rigidity of PLGA 
microneedles. Representative examples of suitable such 
materials include water insoluble inorganic materials, such as 
35 
aluminum hydroxide, aluminum phosphate, and zinc oxide. 
Generally, additive particles should be sufficiently small 
that they do not alter the exterior shape of the microneedles. 
Particles of additives typically are much smaller than the 
dimensions of the microneedles, for example, so they can 
form numerous microdomains within a continuous polymeric 
The first function above is used in the making of porous 
microneedles. Voids are formed in the microneedles upon 
removal of the pore forming agent additive before insertion. 
The selection of pore forming agent is based on its physical or 
chemical properties required for removal (e.g., solubility, 
volatilization or melting temperature) and compatibility with 
the polymer and/or drug, for example. Preferably, the pore 
forming agent is immiscible in the main structural component 
40 matrix. In another embodiment, there are sequential domains 
of polymer and additive (e.g., layers of polymer separated by 
layers of additive), in a laminate structure. In a further 
embodiment, the bores of hollow microneedles are filled with 
additive, forming a temporary plug which dissolves upon of the microneedle (e.g., polymer), and is biocompatible or at 
least leaves only biocompatible residues, if any. Representa-
tive pore forming agents include sodium chloride, sodium 
phosphate, sodium carbonate, potassium chloride, and vola-
tile salts, such as ammonium bicarbonate, ammonium 
acetate, ammonium chloride, ammonium benzoate and mix-
tures thereof, as well as iodine, phenol, benzoic acid (as acid 50 
not as salt), and naphthalene. Other examples of specific salts 
include Na2HP04 , Na2HP04 -12H20 (a salt hydrate), and 
K2 HP04 . Salts listed as pharmaceutical excipients approved 
45 insertion, thereby permitting release of drug through the bore. 
The additive, e.g., salt, in this embodiment provides two 
functions: it enhances the structural rigidity of the micron-
eedles during insertion and prevents leakage of drug before 
use. 
The additive is selected based on its ability to be removed 
and/or its ability to alter the structural properties of the 
microneedle. Removal can be conducted in several ways, for 
example, by a phase change, such as dissolution, degradation, 
vaporization, liquefaction, or a combination thereof. In one by the FDA are typically preferred. Several classes of com-
pounds other than salt also can be used. 55 embodiment, the needles are made under conditions where 
the main material and the needle are both solids. Upon warm-
ing, the additive changes phase (e.g., melt) but the bulk mate-
rial forming the microneedle structure does not. For example, 
The use of a hydrate may be preferred. In hydrates, the 
water dissociates from the salt at a given temperature. Thus, 
below that dissociation temperature, the hydrate is a solid. 
Above that temperature, the water dissociates and forms liq-
uid water, which can dissolve some or all of the salt. Thus, you 60 
can get a solid to liquid phase transition. In the case of 
Na2HP04 -12H20, this transition occurs just below body tem-
perature. Thus, the hydrate is solid at room temperature (as-
suming it is not too hot), but becomes liquid at body tempera-
ture. This is useful for forming voids. These voids could be 65 
formed during processing by raising the temperature. They 
could be formed in the body. If so, the formulation should 
the additive can be ice which is subsequently melted. Another 
option is that a hydrate is used. Below a certain temperature, 
the hydrate is intact and above that temperature, the water 
dissociates from the other material (e.g., salt). Alternatively, 
the additive is a gel sensitive to temperature, pH, or another 
stimuli. Many triggers are possible for inducing a phase 
change which can cause the additive to be removed, either 
during processing or within the body. One of skill in the art 
can select the appropriate material/structure for the particular 
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application. See, for example, Pettifor, Bonding and Struc-
ture of Molecules and Solids, (New York, Oxford University 
Press 1995); Hull & Clyne, An Introduction to Composite 
Materials (2d ed., New York, Cambridge University Press 
1996). 
h. Molecules to Be Delivered 
14 
penetrate through the epidermis 16 into the dermis 18 (as 
described below), thereby avoiding contacting nerves and 
reducing the potential for causing pain. In such applications, 
the actual length of the microneedles may be longer, since the 
portion of the microneedles distal the tip may not be inserted 
into the skin; the uninserted length depends on the particular 
device design and configuration. The actual (overall) height 
or length of microneedles 12 should be equal to the insertion 
depth plus the uninserted length. Other embodiments using 
10 sufficiently small microneedles may penetrate into the dermis 
without causing pain. In alternative embodiments, the 
microneedle length and/or penetration depth may be greater 
than illustrated, for example for the delivery of vaccine to 
dendritic cells at the dermis interface. The microneedles 12 
Essentially any drug can be delivered using the micron-
eedle devices described herein. As used herein, the term 
"drug" refers to an agent which possesses therapeutic, pro-
phylactic, or diagnostic properties in vivo, for example when 
administered to an animal, including mammals, such as 
humans. This includes ex vivo or in vitro delivery into cells or 
single cell animals. Examples of suitable therapeutic and/or 
prophylactic active agents include proteins, such as hor-
mones, antigens, and growth factors; nucleic acids, such as 15 
antisense molecules; and smaller molecules, such as antibi-
otics, steroids, decongestants, neuroactive agents, anesthet-
ics, and sedatives. Examples of suitable diagnostic agents 
include radioactive isotopes and radioopaque agents, metals, 
gases, labels including chromatographic, fluorescent or enzy- 20 
matic labels. 
can be solid or porous, and can include one or more bores 
connected to upper portion 11. 
3. Methods of Making Microneedle Devices 
The microneedle devices are made by microfabrication 
processes that are based on established methods used to make 
integrated circuits, electronic packages and other microelec-
tronic devices, augmented by additional methods used in the 
A preferred drug is a vaccine. The term vaccine includes 
viral or DNA substituents, for therapeutic or prophylactic 
applications. 
The drug can be or include a peptide, protein, carbohydrate 
(including monosaccharides, oligosaccharides, and polysac-
charides), nucleoprotein, mucoprotein, lipoprotein, glyco-
protein, nucleic acid molecules (including any form of DNA 
such as cDNA, RNA, or a fragment thereof, oligonucleotides, 
and genes), nucleotide, nucleoside, lipid, biologically active 
organic or inorganic molecules, or combination thereof. 
The amount of drug can be selected by one of skill in the 
art, based, for example on the particular drug, the desired 
effect of the drug at the planned release levels, and the time 
span over which the drug should be released. 
Other agents which can be released include perfumes, 
insect repellents, sun block, and dyes or other coloring agents. 
field of micromachining and micromolding. Three-dimen-
sional arrays of microneedles can be fabricated, for example, 
using combinations of dry etching processes; micromold cre-
25 ation in lithographically-defined polymers and selective side-
wall electroplating; or direct micromolding techniques using 
epoxy mold transfers. These processes are described in U.S. 
Ser. No. 09/095,221, filed Jun. 10, 1998, and U.S. Ser. No. 
09/316,229, filed May 21, 1999, by Prausnitz, et al., and in 
30 PCT WO 99/64580 and PCT WO 00/74763, and are incorpo-
rated herein by reference, with preferred and additional meth-
ods described below. 
Polymer microneedles can be fabricated by (i) etching the 
polymer microneedle directly, (ii) etching a mold and then 
35 filling the mold to form the polymer microneedle product, or 
(iii) etching a microneedle master, using the master to make a 
mold, and then filling the mold to form the polymer micron-
eedle replica (of the master). Details of these processes are 
described below. 
Essentially any drug can be incorporated into microneedles 
formed of other materials, so long as the drug can survive the 
fabrication process conditions to which it is exposed follow- 40 
ing its introduction into the process, for example, high or low 
temperatures and pressures and exposure to solvents and 
mechanical forces. For example, drugs that can be impreg-
nated in polymeric microneedles are those known to be 
capable of incorporation into polymeric micro spheres. 
Micromolding 
One method for forming microneedles is to use microfab-
rication techniques such as photo lithography, plasma etching, 
or laser ablation to make a mold form (A), transferring that 
mold form to other materials using standard mold transfer 
45 techniques, such as embossing or injection molding (B), and 
reproducing the shape of the original mold form (A) using the 
newly-created mold (B) to yield the final microneedles (C). 
Alternatively, the creation of the mold form (A) could be 
skipped and the mold (B) could be microfabricated directly, 
The selection of drugs capable of formation into micron-
eedles, however, is more limited. The drug preferably is a 
solid or capable of being made into a solid. It is envisioned, 
however, that the drug also can be a liquid or gel. 
i. Transdermal Microneedle Device 
FIG. 5 is a side elevational view of a schematic of an 
embodiment of the microneedle device inserted into unde-
formed skin. The device 10 includes an upper portion or 
substrate 11 from which a plurality of microneedles 12 pro-
trude. The upper portion 11 of the device can be solid or 
hollow, and may include multiple compartments. In a pre-
ferred embodiment for drug delivery, the upper portion 11 
contains one or more drugs to be delivered. It is also preferred 
that the upper portion include one or more sensors and/or an 
apparatus (e.g., pump or electrode) to drive provide/ direct the 
force) transport of the drug or other molecules. 
50 which could then be used to create the final microneedles (C). 
In a preferred method, polymeric microneedles are made 
using microfabricated molds. For example, epoxy molds can 
be made as described above and injection molding techniques 
can be applied to form the microneedles in the molds (Weber, 
55 et al., "Micromolding-a powerful tool for the large scale 
production of precise microstructures", Proc. SPIE-Interna-
tional Soc. Optical Engineer. 2879:156-67 (1996); Schift, et 
al., "Fabrication of replicated high precision insert elements 
for micro-optical bench arrangements" Proc. SPIE-Interna-
60 tional Soc. Optical Engineer. 3513:122-34 (1998)). These 
micromolding techniques may be preferred over other tech-
niques, as they may provide relatively less expensive replica-
tion, i.e. lower cost of mass production. In a preferred 
The diameter and length of the microneedle both affect 
pain as well as functional properties of the needles. In one 
embodiment for transdermal applications, the "insertion 
depth" of the microneedles 12 is less than about 100 µm, more 65 
preferably about 30 µm, so that insertion of the microneedles 
embodiment, the polymer is biodegradable. 
In one embodiment, micromolds are filled with liquid 
monomer or a solution of monomer, the monomer is poly-
merized, and the polymer is directly or indirectly converted to 12 into the skin through the stratum corneum 14 does not 
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a solid form in the shape of the microneedles. Alternatively, 
the micromold is filled with polymer powder, heated to melt 
the polymer, and then cooled to solidify the polymer in the 
shape of the microneedles. The polymer powder also can be 
molded by compression molding. In a preferred embodiment, 
polymer melting is conducted under reduced pressure (e.g., 
vacuum conditions) in order to pull the polymer into the mold 
and displace any trapped gases, thereby minimizing or elimi-
nating the formation of void defects in the microneedles. 
Polymer can also be pulled into the mold by centrifugation. 
This approach overcomes the surface tension/wetting prob-
lems which can occur in large scale molding operations. 
FIG. 1 illustrates the steps used in one method of molding 
polylactide or polylactide/glycolide microneedles using a 
silicone mold. The silicone mold is made by first forming a 
mold insert, i.e. an array of microneedles made by any 
method, e.g., reactive ion etching (RIE) a substrate having 
chromium masking (FIG. la). The mold insert (FIG. lb) is 
then covered with polydimethylsiloxane (PDMS), under 
vacuum conditions to remove bubbles which can form and be 
trapped between the PDMS and insert (FIG. le). The PDMS 
is then cured to form a silicone mold. The microneedles are 
removed from the mold, rendering the mold ready to use to 
mold other microneedles (FIG. ld). The silicone mold is then 
filled with glycolide orpolylactide/glycolide powder (with or 
without sodium chloride powder mixed therein) (FIG. le). 
The polymer powder is then melted and/or compressed, pref-
erably under vacuum, thereby forming polymer micron-
eedles. Then, the polymer is cooled, and the microneedles are 
removed from the mold (FIG. lj). The NaCl can function as a 
reinforcing structure, yielding added mechanical strength, or 
as a pore-forming agent which is dissolved out to leave a 
polymer having an open pore structure (FIG. lg) as further 
described herein. 
In certain embodiments, a micromold is filled in a two-step 
process, wherein the first step includes coating a first layer of 
a first material into the mold and solidifying the first material, 
and the second step includes filling the remainder of the mold 
with a second material. The process results in microneedles 
having an outer surface coating of the first material covering 
16 
the same fashion as described above. Then, it is used by 
techniques described herein to be replicated in polymer. 
Other variations of the fabrication process are described in 
the Examples below. 
5. Microneedle Device Applications 
The device may be used for single or multiple uses for rapid 
transport across a biological barrier or may be left in place for 
longer times (e.g., hours or days) for long-term transport of 
molecules. Depending on the dimensions of the device, the 
10 application site, and the route in which the device is intro-
duced into (or onto) the biological barrier, the device may be 
used to introduce or remove molecules at specific locations. 
As discussed above, FIG. 5 shows a side elevational view 
of a schematic of a preferred embodiment of the microneedle 
15 device 10 in a transdermal application. The device 10 is 
applied to the skin such that the microneedles 12 penetrate 
through the stratum corneum and enter the viable epidermis 
so that the tip of the microneedle at least penetrates into the 
viable epidermis. In a preferred embodiment, drug molecules 
20 in a reservoir within the upper portion 11 flow through or 
around the microneedles and into the viable epidermis, where 
the drug molecules then diffuse into the dermis for local 
treatment or for transport through the body. The needles also 
could be made and used to penetrate directly to or into the 
25 dermis. 
To control the transport of material out of or into the device 
through the microneedles, a variety of forces or mechanisms 
can be employed. These include pressure gradients, concen-
tration gradients, electricity, ultrasound, receptor binding, 
30 heat, chemicals, and chemical reactions. Mechanical or other 
gates in conjunction with the forces and mechanisms 
described above can be used to selectively control transport of 
the material. 
In particular embodiments, the device should be "user-
35 friendly." For example, in some transdermal applications, 
affixing the device to the skin should be relatively simple, and 
not require special skills. This embodiment of a microneedle 
may include an array of microneedles attached to a housing 
containing drug in an internal reservoir, wherein the housing 
40 has a bioadhesive coating around the microneedles. The 
patient can remove a peel-away backing to expose an adhe-
sive coating, and then press the device onto a clean part of the 
skin, leaving it to administer drug over the course of, for 
a core of the second material. This is particularly useful to 
avoid a burst release effect in drug delivery. For example, the 
first material could be a polymer coating and the second 
material could be a drug/polymer mixture, whereby the outer 45 
coating controls the time and/or rate of release of drug from 
the microneedle. 
example, several days. 
a. Delivery of Drug and Other Molecules 
Essentially any drug can be delivered using these devices. 
Drugs can be proteins, enzymes, polysaccharides, polynucle-
otide molecules, and synthetic organic and inorganic com-
pounds. Representative agents include vaccines, anti-infec-
Micro fabrication 
Microneedles can be fabricated by (i) etching the micron-
eedles directly, (ii) etching a mold and then filling the mold to 
form the microneedle product, or (iii) etching a microneedle 
master, using the master to make a mold, and then filling the 
mold to form the microneedle replica (of the master). The 
Examples below illustrate various embodiments of these 
techniques. 
Microcutting/Microshaping 
Rather than using chemical etching processes (e.g., RIE, 
photolithography) to define the microneedle or mold shape, 
special physical cutting tools with very sharp tips/cutting 
edges can be used. This micronshaping approach can be used 
to directly make microneedles, or can be used to make molds 
which are used to make microneedles. To directly make 
microneedles, a substrate (e.g., a piece of polymer or metal) is 
cut using a small cutting tool, which could be, for example, a 
microdiamond profiled in a wedge shape. One or more of 
these tools are used to cut the substrate into the desired shape. 
To make microneedles from a mold, the mold is prepared in 
50 tives, hormones, such as insulin, growth regulators, drugs 
regulating cardiac action or blood flow, and drugs for pain 
control. The drug can be for local treatment or for regional or 
systemic therapy. The following are representative examples, 
55 
and disorders they are used to treat: 
Calcitonin, osteoporosis; Enoxaprin, anticoagulant; Etan-
ercept, rheumatoid arthritis; Erythropoietin, anemia; Fenta-
nyl, postoperative and chronic pain; Filgrastin, low white 
blood cells from chemotherapy; Heparin, anticoagulant; 
Insulin, human, diabetes; Interferon Beta la, multiple scle-
60 rosis; Lidocaine, local anesthesia; Somatropin, growth hor-
mone; and Sumatriptan, migraine headaches. 
In this way, many drugs can be delivered at a variety of 
therapeutic rates. The rate can be controlled by varying a 
number of design factors, including, but not limited to, the 
65 outer diameter of the microneedle, the number and size of 
pores or chamiels in each microneedle, the number and size 
(i.e. length) ofmicroneedles in an array, the structure, mate-
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rials of construction and, permeability of the microneedle, the 
magnitude and frequency of application of the force driving 
the drug through the microneedle and/or the holes created by 
the microneedles. For example, devices designed to deliver 
drug at different rates might have more microneedles for 
delivery that is more rapid and fewer microneedles for less 
rapid delivery. As another example, a device designed to 
deliver drug at a variable rate could vary the driving force 
(e.g., pressure gradient controlled by a pump) for transport 
according to a schedule which was pre-programmed or con- 10 
trolled by, for example, the user or his doctor. The devices can 
be affixed to the skin or other tissue to deliver drugs continu-
ously or intermittently, for durations ranging from a few 
seconds to several hours or days. 
One of skill in the art can measure the rate of drug delivery 15 
for particular microneedle devices using in vitro and in vivo 
methods known in the art. For example, to measure the rate of 
transdermal drug delivery, human cadaver skin mounted on 
standard diffusion chambers can be used to predict actual 
rates. See Hadgraft & Guy, eds., Transdermal Drug Delivery: 20 
Developmental Issues and Research Initiatives (Marcel Dek-
ker, New York 1989); Bronaugh & Maibach, Percutaneous 
Absorption, Mechanisms-Methodology-Drug Delivery 
(Marcel Dekker, New York 1989). After filling the compart-
ment on the dermis side of the diffusion chamber with saline, 25 
a microneedle array is inserted into the stratum corneum; a 
drug solution is placed in the reservoir of the microneedle 
device; and samples of the saline solution are taken over time 
and assayed to determine the rates of drug transport. 
In a preferred embodiment, biodegradable microneedles 30 
can be used as the entire drug delivery device. For example, 
the microneedles can be formed of a biodegradable polymer 
containing a dispersion of an active agent for local or sys-
temic delivery. The agent could be released overtime, accord-
ing to a profile determined by the composition and geometry 35 
of the microneedles, the concentration of the drug and other 
factors. In this way, the drug reservoir is within the matrix of 
one or more of the microneedles. 
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material that dissolves (e.g., a salt) or is otherwise removed 
following insertion of the microneedle. This removal can be 
controlled to occur after a period following insertion, for 
example, by selecting a material that degrades or dissolves 
slowly in vivo. In one embodiment, the breakage of the 
microneedle from the substrate indicates that the treatment is 
complete, functioning as a timer in effect and indicating that 
the device backing should be removed and a new microneedle 
device applied elsewhere on the biological barrier. 
Moreover, the size and shape of the portion of micron-
eedles which break off can be controlled not only for specific 
drug release patterns, but also for specific interactions with 
cells in the body. For example, objects ofa few microns in size 
are known to be taken up by macrophages. The portions of 
microneedles that break off can be controlled to be bigger or 
smaller than that to prevent uptake by macrophages or can be 
that size to promote uptake by macrophages, which can be 
desirable for delivery of vaccines. 
b. Diagnostic Sensing of Body Fluids (Biosensors) 
One embodiment of the devices described herein may be 
used to remove material from the body across a biological 
barrier, i.e. for minimally invasive diagnostic sensing. For 
example, fluids can be transported from interstitial fluid in a 
tissue into a reservoir in the upper portion of the device. The 
fluid can then be assayed while in the reservoir or the fluid can 
be removed from the reservoir to be assayed, for diagnostic or 
other purposes. For example, interstitial fluids can be 
removed from the epidermis across the stratum corneum to 
assay for glucose concentration, which should be useful in 
aiding diabetics in determining their required insulin dose. 
Other substances or properties that would be desirable to 
detect include lactate (important for athletes), oxygen, pH, 
alcohol, tobacco metabolites, and illegal drugs (important for 
both medical diagnosis and law enforcement). 
The sensing device can be in or attached to one or more 
microneedles, or in a housing adapted to the substrate. Sens-
ing information or signals can be transferred optically (e.g., In one variation of this embodiment, the microneedles may 
be purposefully sheared off from the substrate after penetrat-
ing the biological barrier. In this way, a portion of the micron-
eedles would remain within or on the other side of the bio-
logical barrier and a portion of the microneedles and their 
substrate would be removed from the biological barrier. In the 
case of skin, this could involve inserting an array into the skin, 
manually or otherwise breaking off the microneedles, or the 
tip portion thereof, and then removing the substrate and base 
portion of the microneedles, if any. The portion of the micron-
eedles which remains in the skin or other biological barrier 
then releases drug over time according to a profile determined 
by the composition and geometry of the microneedles, the 
concentration of the drug, and other factors. The release of 
drug from biodegradable microneedles can be controlled by 
the rate of polymer degradation. Complex release patterns 
can be provided using microneedles formed of multiple mate-
rials, for example by fabricating microneedles having mul-
tiple layers of drugs and/or matrices of different materials. 
40 refractive index) or electrically (e.g., measuring changes in 
electrical impedance, resistance, current, voltage, or combi-
nation thereof). For example, it may be useful to measure a 
change as a function of change in resistance of tissue to an 
electrical current or voltage, or a change in response to chan-
The microneedles can release drugs for local or systemic 
effect, or can release other agents, such as perfumes; insect 
repellent; sun block; and dyes or other coloring agents, useful 
for example in making tattoos. 
Microneedle shape and content can be designed to control 
the breakage of microneedles. For example, an indentation 
can be introduced into microneedles either at the time of 
fabrication or as a subsequent step. In this way, microneedles 
preferentially break at the site of the indentation. Alterna-
tively, a section of the microneedle can be fabricated of a 
45 nel binding or other criteria (such as an optical change) 
wherein different resistances are calibrated to signal that 
more or less flow of drug is needed, or that delivery has been 
completed. 
In one embodiment, one or more microneedle devices can 
50 be used for (1) withdrawal of interstitial fluid, (2) assay of the 
fluid, and/or (3) delivery of the appropriate amount ofa thera-
peutic agent based on the results of the assay, either automati-
cally orwithhuman intervention. For example, a sensor deliv-
ery system may be combined to form, for example, a system 
55 which withdraws bodily fluid, measures its glucose content, 
and delivers an appropriate amount of insulin. The sensing or 
delivery step also can be performed using conventional tech-
niques, which would be integrated into use of the microneedle 
device. For example, the microneedle device could be used to 
60 withdraw and assay glucose, and a conventional syringe and 
needle used to administer the insulin, or vice versa. 
In an alternate embodiment, microneedles may be pur-
posefully sheared off from the substrate after penetrating the 
biological barrier, as described above. The portion of the 
65 microneedles which remain within or on the other side of the 
biological barrier could contain one or more biosensors. For 
example, the sensor could change color as its output. For 
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microneedles sheared off in the skin, this color change could 
be observed through the skin by visual inspection or with the 
aid of an optical apparatus. 
The microneedles can also be used for aerosolization or 
delivery for example directly to a mucosa! surface in the nasal 5 
or buccal regions or to the pulmonary system. 
The microneedle devices disclosed herein also should be 
useful for controlling transport across tissues other than skin. 
For example, microneedles can be inserted into the eye across 
or into, for example, conjunctiva, sclera, and/or cornea, to 10 
facilitate delivery of drugs into the eye. Similarly, micron-
eedles inserted into the eye can facilitate transport of fluid out 
of the eye, which may be of benefit fortreatment of glaucoma. 
Microneedles may also be inserted into the buccal (oral), 
nasal, vaginal, or other accessible mucosa to facilitate trans- 15 
port into, out of, or across those tissues. For example, a drug 
may be delivered across the buccal mucosa for local treatment 
in the mouth or for systemic uptake and delivery. As another 
example, microneedle devices may be used internally within 
the body on, for example, the lining of the gastrointestinal 20 
tract to facilitate uptake of orally-ingested drugs or the lining 
of blood vessels to facilitate penetration of drugs into the 
vessel wall. For example, cardiovascular applications include 
using microneedle devices to facilitate vessel distension or 
immobilization, similarly to a stent, wherein the micron- 25 
eedles/substrate can function as a "staple-like" device to pen-
etrate into different tissue segments and hold their relative 
positions for a period to permit tissue regeneration. This 
application could be particularly useful with biodegradable 
devices. These uses may involve invasive procedures to intro- 30 
duce the microneedle devices into the body or could involve 
swallowing, inhaling, injecting or otherwise introducing the 
devices in a non-invasive or minimally-invasive manner. 
c. Delivery of Energy 
Other than transport of drugs and biological molecules, the 35 
microneedles may be used to transmit or transfer other mate-
rials and energy forms, such as light, electricity, heat, or 
pressure. The microneedles, for example, could be used to 
direct light to specific locations within the body, in order that 
the light can directly act on a tissue or on an intermediary, 40 
such as light-sensitive molecules in photodynamic therapy. 
The present invention will be further understood with ref-
erence to the following non-limiting examples. 
20 
When salt was included, it was entrapped within the poly-
lactide melt. After quenching, the polylactide needle array 26 
was removed from the silicone mold (FIG. l.f). By placing in 
water, salt could be removed from the polylactide needles, 
leaving pores within the needles. FIG. lg illustrates the right 
microneedle 27 in water 28, wherein a series of pores 29 have 
been formed. 
Resulting polylactide microneedles were 200 microns long 
and 80 microns wide at their base, which was the same shape 
as the original silicon needles used to make the mold. 
EXAMPLE2 
Fabrication of Solid PLA Microneedles Using RIE 
A layer of polylactide 30 was coated onto a silicon or glass 
substrate 32 (FIG. 2a). A thin film of aluminum 34 was 
deposited on the upper surface of the polylactide layer 30 
(FIG. 2b). Then, photoresist 36 was coated onto the upper 
surface of the aluminum film 34 (FIG. 2c). Ultraviolet (UV) 
light was then shined onto the photoresist through an optical 
mask 38 containing dark circles having the shape of the 
microneedle bases (FIG. 2d). The photoresist was then devel-
oped (FIG. 2e ). The aluminum not covered by photoresist was 
then etched away and the remaining photoresist was removed 
(FIG. 2.f). This left a pattern of aluminum dots 40 forming a 
physical mask having the same geometry as the optical mask. 
Finally, using reactive ion etching (RIE), the polylactide was 
etched; the aluminum mask defined the size of the micron-
eedle base while the RIE gas composition defined the taper of 
the needles (FIG. 2g). Microneedles needles made in this 
fashion were solid and measured 80 microns at their base and 
100 microns in length. 
It should be noted that different layers of polymer could 
have been sequentially formed together as polymer layer 30, 
such that the resulting needles were formed of layers of dif-
ferent materials. For example, the tip portion could be formed 
of a first polymeric material having a lower rate ofbiodegra-
dation than the base or shaft portion. FIG. 3 shows one 
example of microneedles formed by applying this etching 
technique to a multilayer polymer structure, yielding a device 
having microneedles formed of four different materials. The 
EXAMPLE 1 
Fabrication of Solid Polylactide Microneedles Using 
Molding 
45 choice of materials can be selected to provide desired 
mechanical strength, degradation rates, release profiles, and 
other properties. 
Solid silicon microneedle arrays were fabricated as previ- 50 
ously described (S Henry, et al. (1998) "Microfabricated 
microneedles: A novel approach to transdermal drug deliv-
ery," J. Pharm. Sci. 87:922-25). The final steps ofthis process 
are shown in FIGS. la and lb, with array of solid silicon 
microneedles 20 resulting from reactive ion etching of silicon 55 
substrate 19 with chromium masks 21. 
Then, a polydimethylsiloxane (PDMS) mold of the silicon 
microneedle array was made under vacuum (FIG. le). After 
curing the PDMS 23 and removing the silicon microneedle 
array 20, a silicone mold 22 of the microneedles resulted 60 
(FIG. ld). This mold was then filled either with polylactide or 
with polylactide (e.g., 90%) and NaCl (e.g., 10%) in solid 
form. FIG. le shows the left and center individual micron-
eedle molds containing only polylactide particles 24 and the 
right individual microneedle mold containing a mixture of 65 
polylactide particles 24 and NaCl particles 25. Heating under 
vacuum melted the polylactide. 
EXAMPLE3 
Fabrication of Hollow PLA Microneedles 
SU-8 epoxy photoresist 60 was coated onto a silicon wafer 
substrate 62 containing an array of holes 64, which were 100 
microns in diameter and etched into the silicon using deep 
reactive ion etching (FIG. 6a). UV was then exposed through 
a dark optical mask 66 containing transparent regions having 
a donut shape onto the SU-8 with photoinitiator (FIG. 6b). 
The UV-exposed portions 68 of the SU-8 were crosslinked 
(FIG. 6c). The SU-8 was then developed with propylene 
glycol methyl ether acetate (PGMEA) to remove the unex-
posed SU-8 (FIG. 6d), resulting in hollow cylindrical struc-
tures 68. These cylindrical structures 68 then were used to 
make a mold 70 from PDMS (FIG. 6e). This mold 70 was 
filled with polylactide (PLA) powder 72 which was then 
melted (FIG. 6.f). After quenching, the polylactide needle 
array 74 was removed from the silicone mold (FIG. 6g). The 
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process yielded hollow polylactide microneedles having non-
tapered walls, an outer diameter of 100 microns, and a length 
of300 microns. 
22 
The pattern exposed only one side of the cylindrical structures 
104. The exposed sacrificial polymer layer and cylindrical 
structures were then etched by RIE (FIG. Sf). Sacrificial poly-
mer was removed by organic solvent, resulting in a structure 
EXAMPLE4 5 110 having SU-8 microneedles with beveled tips 111 (FIG. 
Fabrication of Pointed Solid PLA Microneedles 
Sg). 
The structure 110 was then used to make a mold 112 of 
PDMS, which can be used to make a replica structure, for 
example from a biodegradable material. The silicone mold 
10 
112 was then filled with polyglycolide polymer powder 113 
(FIG. Sh). The polymer powder was then melted under 
vacuum, thereby forming polymer microneedle structure 114 
(FIG. Si). FIG. lOa shows an array of these beveled micron-
eedles, and FIG. 1 Ob is a close-up photograph ofan individual 
beveled microneedle. 
SU-8 epoxy photoresist (with photoinitiator) SO was 
coated onto a silicon wafer substrate S2 (FIG. 7a). UV was 
then exposed through a dark optical mask S4 containing trans-
parent regions having a donut shape onto the SU-8 with photo 
initiator (FIG. 7b). The UV-exposed portions S6 of the SU-8 
were crosslinked (FIG. 7c). The SU-8 was then developed 
with propylene glycol methyl ether acetate (PGMEA) to 15 
remove the unexposed SU-8 (FIG. 7d). The resulting hollow 
cylindrical structures SS were coated with metal 90 on the top 
surface of the cylindrical structure of crosslinked SU-8 by 
electron beam (E-Beam) metal deposition (FIG. 7e). This 
metal layer 90 serves a protective or shielding function during 20 
subsequent reactive ion etching. The metal could be chro-
mium, titanium, or aluminum, for example. SU-8 without 
photo initiator 92 was then used to fill space between cylin-
ders to protect them from side etching of the cylindrical 
structures SS (FIG. 7j). To make sharp tips 94 on the cylin- 25 
drical structures SS, the SU-8 epoxy was etched by reactive 
ion etching (RIE) (FIG. 7g) and developed again by PGMEA 
to remove SU-8 without photoinitiator (FIG. 7h). This 
resulted in cylindrical structures SS (i.e. microneedles ), made 
of crosslinked SU-8, having sharp tips 94 created during the 30 
reactive ion etching. 
This microneedle structure 95 was used to make a mold 96 
from PDMS (FIG. 7i), which can be used to make a replica 
structure, for example from a biodegradable material. The 
mold 96 was filled with a mixture 97of15% NaCl and 85% 35 
EXAMPLE 6 
Fabrication Of PGA Beveled Microneedles With 
Channels 
SU-8 epoxy photoresist with photoinitiator was spin 
coated onto a silicon wafer. The coated wafer was exposed to 
UV (365 nm) through mask pattern having circular shape 
with square indention. The UV-exposed portion of the epoxy 
was crosslinked. The non-crosslinked portion of the epoxy 
was then developed with PGMEA. The square indention 
causes a longitudinal channel to be formed on the side of 
cylindrical structures. FIG. 9 shows an array of these micron-
eedle structures having a longitudinal channel. 
The resulting cylindrical structures with the channel were 
then filled with a sacrificial, thermoplastic polymer layer up 
to the height of cylindrical structure, under vacuum. Then, a 
copper layer was deposited by e-beam deposition onto the 
sacrificial polymer layer and cylindrical structures. This cop-
per layer was then etched with a diluted sulfuric acid solution 
polymer solution (50% polylactic acid and 50% methylene 
chloride) (FIG. 7j). The polymeric material in the mold was 
then dried and melted under vacuuming to form polymeric 
microneedles and an integral substrate, which were then 
removed from the mold (FIG. 7k). The resulting microneedles 
9S were 100 microns in diameter, along the shaft portion, and 
400 microns long, with a sharp, tapered tip portion a few 
microns in length. 
to make an etched pattern, as described in Example 5. Sub-
sequently, the sacrificial polymer layer and cylindrical notch 
structures of crosslinked SU-8 was etched by RIE and the 
sacrificial polymer was removed using an organic solvent. 
The resulting beveled and notch microneedle structure then 
was used to make a silicone mold that can be used, as 
40 described in Example 5, to make a replica microneedle struc-
tures, for example from a biodegradable material. 
EXAMPLES 
Fabrication of Solid Microneedles Having A Beveled 
Tip 
45 
EXAMPLE 7 
Fabrication Of Beveled Microneedles Of PGA With 
AProtien 
Carboxy methyl cellulose (CMC) and bovine serum albu-
min (BSA) were dissolved in water to make 4% CMC solu-
50 ti on and 0.5% BSA with high viscosity. An array of polymeric 
beveled microneedles having an open longitudinal channel, 
made as described in the first part of Example 6, was placed 
into the CMC solution. A vacuum was then applied to fill the 
channels in the microneedles with CMC solution. The 
Microneedle devices were made by microfabrication pro-
cesses based on established methods (e.g., used to make inte-
grated circuits, electronic packages and other microelectronic 
devices). SU-8 epoxy photoresist with photoinitiator 100 was 
coated onto a silicon wafer substrate 102 (FIG. Sa). Then UV 
(365 nm) was exposed through optical mask 103 transparent 55 
regions having circular shapes onto the SU-8 with a photo-
initiator (FIG. Sb). The UV-exposed part 104 was 
crosslinked. The non-crosslinked SU-8 105 was then devel-
oped with PGMEA (propyl glycol methyl ether acetate). 
Between the resulting cylindrical structures 104, a sacrifi- 60 
cial thermoplastic polymer layer 106 was filled up to the 
height of cylindrical structures 104 (FIG. Sc). The polymer 
layer 106 was used to protect the cylindrical structures from 
side etching. The polymer layers 104 and 106 then were 
coated with a copper layer 1 OS by electron beam metal depo- 65 
sition (FIG. Sd). This copper layer lOS was etched by H20/ 
H2 S04 /H20 2 =10/1/1 to make the desired pattern (FIG. Se). 
microneedles were then washed slightly with water to remove 
residual CMC outside of the channel. The microneedles were 
then allowed to dry. The process resulted in PGA micron-
eedles having a channel filled with BSA in a CMC matrix. 
The BSA release rate would be controlled, in part, by the 
properties of the CMC. 
EXAMPLE 8 
Fabrication of Microneedles Having An Obelisk 
Shape 
Silicon nitride was deposited onto a silicon wafer 120 to a 
thickness of 4000 A by chemical vapor deposition (CVD), to 
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make a hard mask for etching the silicon with KOH (FIG. 
lla). The silicon nitride layer 122 was etched using reactive 
ion etching (RIE) with SF 4 +02 chemistry. The silicon nitride 
was etched until the silicon was exposed, about 9.5 minutes 
(FIG. llb ). Then the photoresist was removed using RIE with 
0 2 chemistry, about 10 minutes. Alternatively, the photoresist 
was removed using warm acetone solvent, which is recom-
mended because the acetone will not attack the silicon nitride. 
24 
EXAMPLE 11 
Insertion And Breakage Of Microneedles Into Skin 
Polymeric microneedles fabricated by the methods 
described herein were inserted into the skin using a force less 
than that which can easily be applied by the experimenter's 
hand. Then, a base of the microneedle array was moved 
vigorously in a direction parallel to the skin surface, thereby Then the structure was placed into an etchant of KOH 
solution 123, which was heated to 75° C. Typical silicon etch 
rates for KOH are about 1.2 micron per minute, but this will 
vary with temperature and concentration. Silicon was etched 
10 selectively breaking off microneedles from their substrate 
near to the base of the array. In this way, the array was 
separated and the individual microneedles remained embed-
ded into the skin. The needles were left in the skin for some to form pyramid structure holes 124 terminating in a sharp 
point (FIGS. 4 and llc). Then, SU-8 epoxy photoresist with 
photoinitiator was coated 126 onto the etched structure (FIG. 15 
lld). Subsequently, a second mask was aligned with the 
wafer, so that a second square pattern 128 could be transferred 
onto epoxy layer 126 in vertical aligmnent with silicon nitride 
patterns 122 (FIG. lle). UV (365 nm) was exposed through 
optical mask transparent regions, crosslinking the exposed 20 
portions. The non-crosslinked epoxy was then developed 
with PGMEA, forming obelisk shaped structures 130. The 
spaces between the obelisk structures then were filled with 
PDMS 129 (FIG. 11/), and the cross linked SU-8 was then 
removed using RIE with 0 2 chemistry, leaving only a PDMS 25 
mold 132 (FIG. Hg). Subsequently, polyurethane was poured 
into the PDMS mold and then crosslinked to form polymeric 
microneedles having an obelisk shape, as shown in FIG. 12. 
A second identical PDMS mold was also made. It was then 
30 filled with polylactide or polyglycolide polymer powder. The 
polymer powder was melted under vacuum to fill the mold 
and form polymer microneedles. The polymer then was 
cooled, and the microneedles were removed from the mold. 
EXAMPLE9 
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time and subsequently removed using forceps. 
Publications cited herein and the material for which they 
are cited are specifically incorporated by reference. Nothing 
herein is to be construed as an admission that the invention is 
not entitled to antedate such disclosure by virtue of prior 
invention. 
Modifications and variations of the methods and devices 
described herein will be obvious to those skilled in the art 
from the foregoing detailed description. Such modifications 
and variations are intended to come within the scope of the 
appended claims. 
We claim: 
1. A device for transport of molecules or energy across or 
into a biological barrier, comprising: 
a plurality of microneedles, wherein each microneedle 
formed of a first molding material, wherein the first 
molding material comprises a mixture of a) a polymer 
first material and b) a second material comprising rigid 
particles dispersed therein, wherein the first molding 
material is micromolded into the plurality of micron-
eedles. 
2. The device of claim 1, wherein the polymer is a biode-
gradable polymer. 
3. The device of claim 2, wherein the polymer is selected 
from the group consisting of poly(lactide )s, poly(glycolide )s, 
poly(lactide-co-glycolide )s, polyanhydrides, polyorthoe-Insertion And Removal Of Microneedles Into Skin In Vitro 
Full thickness skin was obtained from human cadavers. 
The epidermis was separated from the dermis by immersion 
40 sters, polyetheresters, polycaprolactones, polyesteramides, 
poly(butyric acid)s, poly(valeric acid)s, polyhydroxyal-
kanoates, degradable polyurethanes, copolymers thereof, and 
blends thereof. 
in 60° C. water for 2 minutes and then removed using a metal 
spatula. Isolated epidermis was rested onto a piece of tissue 45 
paper and polymeric microneedles fabricated by the methods 
described herein were inserted into the epidermis. The force 
required for insertion of the microneedles into the skin was 
less than that which can easily be applied by the experiment-
er's hand. Microneedles could be inserted and withdrawn 50 
multiple times without breaking. Microscopic observation 
showed holes formed in the skin by the microneedles. 
EXAMPLE 10 
Insertion And Removal Of Microneedles Into Skin In 
Vivo 
55 
Polymeric microneedles fabricated by the methods 60 
described herein were inserted into the skin of human volun-
teers. The force required for insertion of the microneedles 
into the skin was less than that which can easily be applied by 
the experimenter's hand. Microneedles could be inserted and 
withdrawn multiple times without breaking. Microneedles 65 
could be inserted into the skin under conditions for which the 
human subject did not report feeling pain. 
4. The device of claim 1, wherein the polymer is a non-
biodegradable polymer. 
5. The device of claim 1, where in the second material 
comprises a metal. 
6. The device of claim 1, wherein the first molding material 
further comprises a drug. 
7. The device of claim 2, wherein the molding material 
comprises a drug. 
8. The device of claim 7, wherein the drug is a vaccine. 
9. The device of claim 2, wherein the biodegradable poly-
mer is a soluble polymer. 
10. The device of claim 1, wherein the molding material 
comprises a salt or other leachable particle. 
11. The device of claim 1, further comprising a substrate 
from which the plurality of microneedles extend. 
12. The device of claim 1, wherein the microneedles have 
lengths between about 10 and 1000 microns. 
13. The device of claim 12, wherein the microneedles have 
widths between about 10 and 500 microns. 
14. The device of claim 1, wherein the second material 
undergoes a temperature sensitive phase change at human 
body temperature. 
15. The device of claim 14, where in the second material is 
a hydrate. 
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16. The device of claim 1, wherein the first material and 
second material are disposed in a layered relationship with 
respect to each other. 
17. The device of claim 16, wherein the first material and 
second material are disposed in an alternating horizontal 
layer configuration with respect to each other. 
18. The device of claim 1 wherein the polymer first mate-
rial is a porous material and the second material is filled into 
the voids or pores of the first material. 
19. The device of claim 1 wherein the second material is a 10 
rapidly degradable polymer particle. 
20. A device for transport of molecules or energy across or 
into a biological barrier, comprising; 
a plurality of microneedles, each microneedle formed of a 
polymer first material and a second material, wherein the 
15 
second material comprises rigid particles that are dis-
persed throughout at least a portion of the polymer and 
wherein the first material and second material are dis-
posed in a layered relationship with respect to each 20 
other, and wherein the first material and second material 
are disposed in an alternating horizontal layer configu-
ration with respect to each other. 
26 
26. The device of claim 20, wherein the second material 
comprises a vaccine. 
27. A device for transport of molecules or energy across or 
into a biological barrier comprising; 
a plurality of microneedles, each microneedle formed of a 
first molding material, wherein the first molding mate-
rial comprises a mixture of a) a polymer first material 
and b) a second material, comprising rigid particles dis-
persed therein; and 
a substrate from which the plurality of microneedles 
extend. 
28. The device of claim 27, wherein the polymer first 
material is a biodegradable polymer. 
29. The device of claim 28, wherein the molding material 
comprises a drug. 
30. The device of claim 28, wherein the biodegradable 
polymer is a soluble polymer. 
31. The device of claim 27, wherein the molding material 
further comprises a drug. 
32. The device of claim 27, wherein the second material 
undergoes a temperature sensitive phase change at human 
body temperature. 
33. The device of claim 32, wherein the second material is 
a hydrate. 21. The device of claim 20, further comprising a substrate 
from which the plurality of microneedles extend. 25 34. The device of claim 27, wherein the first material and 
second material are disposed in a layered relationship with 
respect to each other. 
22. The device of claim 20, wherein the polymer is a 
biodegradable polymer. 
23. The device of claim 22, wherein the molding material 
comprises a drug. 
24. The device of claim 22, wherein the biodegradable 30 
polymer is a soluble polymer. 
25. The device of claim 20, wherein the molding material 
further comprises a drug. 
35. The device of claim 34, wherein the first material and 
second material are disposed in an alternating horizontal 
layer configuration with respect to each other. 
36. The device of claim 27, wherein the second material 
comprises a vaccine. 
* * * * * 
